Quantification of CD4 Responses to Combined Antiretroviral Therapy over 5 Years Among HIV-infected Children in Kinshasa, Democratic Republic of Congo

Overview

Journal J Acquir Immune Defic Syndr

Specialty Infectious Diseases

Date 2012 Jun 27

PMID 22732464

Citations 8

Authors

Andrew Edmonds

Marcel Yotebieng

Jean Lusiama

Yori Matumona

Faustin Kitetele

David Nku

Sonia Napravnik

Stephen R Cole

Annelies Van Rie

Frieda Behets

Affiliations

Soon will be listed here.

Abstract

Background: The long-term effects of combined antiretroviral therapy (cART) on CD4 percentage in HIV-infected children are incompletely understood, with evidence from resource-deprived areas particularly scarce even though most children with HIV live in such settings. We sought to describe this relationship.

Methods: Observational longitudinal data from cART-naive children enrolled between December 2004 and May 2010 into an HIV care and treatment program in Kinshasa, Democratic Republic of Congo were analyzed. To estimate the effect of cART on CD4 percentage while accounting for time-dependent confounders affected by prior exposure to cART, a marginal structural linear mean model was used.

Results: Seven hundred ninety children were active for 2090 person-years and a median of 31 months; 619 (78%) initiated cART. At baseline, 405 children (51%) were in HIV clinical stage 3 or 4; 528 (67%) had advanced or severe immunodeficiency. Compared with no cART, the estimated absolute rise in CD4 percentage was 6.8% [95% confidence interval (CI), 4.7% to 8.9%] after 6 months of cART, 8.6% (95% CI, 7.0% to 10.2%) after 12 months, and 20.5% (95% CI, 16.1% to 24.9%) after 60 months. cART-mediated CD4 percentage gains were slowest but greatest among children with baseline CD4 percentage <15. The cumulative incidence of recovery to "not significant" World Health Organization age-specific immunodeficiency was lower if cART was started when immunodeficiency was severe rather than mild or advanced.

Conclusions: cART increased CD4 percentages among HIV-infected children in a resource-deprived setting, as previously noted among children in the United States. More gradual and protracted recovery in children with lower baseline CD4 percentages supports earlier initiation of pediatric cART.

Citing Articles

Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model.

Sharan R, Ganatra S, Bucsan A, Cole J, Singh D, Alvarez X J Clin Invest. 2021; 132(3).

PMID: 34855621 PMC: 8803324. DOI: 10.1172/JCI153090.

Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation.

Panayidou K, Davies M, Anderegg N, Egger M J Int AIDS Soc. 2019; 21(11):e25200.

PMID: 30614622 PMC: 6275813. DOI: 10.1002/jia2.25200.

Continuous quality improvement interventions to improve long-term outcomes of antiretroviral therapy in women who initiated therapy during pregnancy or breastfeeding in the Democratic Republic of Congo: design of an open-label, parallel, group....

Yotebieng M, Behets F, Kawende B, Ravelomanana N, Tabala M, Okitolonda E BMC Health Serv Res. 2017; 17(1):306.

PMID: 28446232 PMC: 5406969. DOI: 10.1186/s12913-017-2253-9.

Characteristics of HIV-Infected Children at Enrollment into Care and at Antiretroviral Therapy Initiation in Central Africa.

Adedimeji A, Edmonds A, Hoover D, Shi Q, DAmour Sinayobye J, Nduwimana M PLoS One. 2017; 12(1):e0169871.

PMID: 28081230 PMC: 5230784. DOI: 10.1371/journal.pone.0169871.

Early Antiretroviral Therapy Initiation and Mortality Among Infants Diagnosed With HIV in the First 12 Weeks of Life: Experiences From Kinshasa, DR Congo and Blantyre, Malawi.

Sheahan A, Feinstein L, Dube Q, Edmonds A, Chirambo C, Smith E Pediatr Infect Dis J. 2017; 36(7):654-658.

PMID: 28060044 PMC: 5468473. DOI: 10.1097/INF.0000000000001539.

References

Ghaffari G, Passalacqua D, Caicedo J, Goodenow M, Sleasman J . Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. Pediatrics. 2004; 114(5):e604-11. DOI: 10.1542/peds.2004-0274. View

Nachman S, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S . Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA. 2000; 283(4):492-8. DOI: 10.1001/jama.283.4.492. View

Greenland S, Pearl J, Robins J . Causal diagrams for epidemiologic research. Epidemiology. 1999; 10(1):37-48. View

Pepe M, Mori M . Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?. Stat Med. 1993; 12(8):737-51. DOI: 10.1002/sim.4780120803. View

Newell M, Patel D, Goetghebuer T, Thorne C . CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?. J Infect Dis. 2006; 193(7):954-62. DOI: 10.1086/500842. View

George E, Noel F, Bois G, Cassagnol R, Estavien L, Rouzier P . Antiretroviral therapy for HIV-1-infected children in Haiti. J Infect Dis. 2007; 195(10):1411-8. DOI: 10.1086/514823. View

De Baets A, Ramet J, Msellati P, Lepage P . The unique features of pediatric HIV-1 in sub-Saharan Africa. Curr HIV Res. 2008; 6(4):351-62. DOI: 10.2174/157016208785132491. View

Petersen M, Wang Y, van der Laan M, Bangsberg D . Assessing the effectiveness of antiretroviral adherence interventions. Using marginal structural models to replicate the findings of randomized controlled trials. J Acquir Immune Defic Syndr. 2006; 43 Suppl 1:S96-S103. DOI: 10.1097/01.qai.0000248344.95135.8d. View

Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T . Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005; 41(1):100-7. DOI: 10.1086/430714. View

10.

Hammer S, Squires K, Hughes M, Grimes J, Demeter L, Currier J . A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337(11):725-33. DOI: 10.1056/NEJM199709113371101. View

11.

Weinberg A, Dickover R, Britto P, Hu C, Patterson-Bartlett J, Kraimer J . Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS. 2008; 22(17):2267-77. PMC: 2748303. DOI: 10.1097/QAD.0b013e3283189bb3. View

12.

Patel K, Hernan M, Williams P, Seeger J, McIntosh K, Van Dyke R . Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis. 2008; 46(4):507-15. DOI: 10.1086/526524. View

13.

Fahey J, Prince H, Weaver M, Groopman J, Visscher B, Schwartz K . Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am J Med. 1984; 76(1):95-100. DOI: 10.1016/0002-9343(84)90756-3. View

14.

van Rossum A, Scherpbier H, van Lochem E, Pakker N, Slieker W, Wolthers K . Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS. 2001; 15(17):2267-75. DOI: 10.1097/00002030-200111230-00008. View

15.

Resino S, Resino R, Micheloud D, Gurbindo Gutierrez D, Leon J, Ramos J . Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis. 2006; 42(6):862-9. DOI: 10.1086/500412. View

16.

Musoke P, Mudiope P, Barlow-Mosha L, Ajuna P, Bagenda D, Mubiru M . Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr. 2010; 10:56. PMC: 2923128. DOI: 10.1186/1471-2431-10-56. View

17.

OBrien D, Sauvageot D, Zachariah R, Humblet P . In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006; 20(15):1955-60. DOI: 10.1097/01.aids.0000247117.66585.ce. View

18.

Eley B, Davies M, Apolles P, Cowburn C, Buys H, Zampoli M . Antiretroviral treatment for children. S Afr Med J. 2006; 96(9 Pt 2):988-93. View

19.

Nikolic-Djokic D, Essajee S, Rigaud M, Kaul A, Chandwani S, Hoover W . Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. J Infect Dis. 2002; 185(3):290-8. DOI: 10.1086/338567. View

20.

Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V . Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J. 2009; 28(6):488-92. DOI: 10.1097/inf.0b013e318194eea6. View